The Endo GUC Trust

 

Notice to Holders of Ranitidine Claims of Endo International PLC and its Affiliated Debtors: 

The Endo Ranitidine Trust dissolved on January 31, 2025 without distribution to any holder of a Rantidine Trust. The ability of the Trust to make a distribution to holder of Ranitidine claims was dependent on recovery of certain contigent assets that ultimately proved to be uncollectible. 

Important:  In order to be eligible to receive distributions from the Endo GUC Trust or Distribution Sub-Trusts, you must submit a Trust Submission Form or Noteholder Trust Submission Form, together with required supporting documentation and IRS Form W-9 or W-8, by no later than September 5, 2024, unless otherwise stated below.  Use this website to submit your Trust Submission Form or Noteholder Trust Submission Form.

The Endo GUC Trust was established for making distributions, directly or indirectly, to certain holders of general unsecured claims against Endo International plc and its affiliates. 

On August 16, 2022, Endo and its affiliated debtors filed voluntary petitions for bankruptcy protection with the United States Bankruptcy Court for the Southern District of New York (Case No. 22-22549 (JLG)).  On April 24, 2024, the Fourth Amended Joint Chapter 11 Plan of Reorganization of Endo and its affiliated debtors became effective.  The Endo GUC Trust will be making distributions in accordance with the terms of the plan of reorganization.

The general unsecured claims whose holders are or may be entitled to receive distributions from the Endo GUC Trust include—

• Notes Claims:  claims under the second lien notes and unsecured notes of Endo and its affiliates (only holders who are Non-Accredited Note Holders are required to submit a Trust Submission Form; see Notice to Second Lien and Unsecured Note Holders on this website);

• Other General Unsecured Claims: claims for damages for rejection of executory contracts or unexpired leases; arising from personal injury (that is not a Mesh Claim or Ranitidine Claim), economic injury, or litigation, or unpaid trade claims, that in each case are not secured by collateral;

• Mesh Claims: claims relating to personal injury resulting from the use of transvaginal surgical mesh products manufactured by Endo or its affiliated debtors;

• Ranitidine Claims: personal injury claims relating to the allegation that the active ingredient in ranitidine medications manufactured by the Endo or its affiliated debtors can break down to form an alleged carcinogen;

• Generics Price Fixing Claims: claims relating to the pricing and sale of generic pharmaceutical products of Endo (the deadline for submitting Trust Submission Forms for these claims is to be annouced); and

• Reverse Payment Claims, consisting of “pay for delay” or “reverse price-fixing” claims, including with respect to Opana® ER, AndroGel®, Exforge®, Seroquel XR®, Xyrem®, Amitiza®, and Colcrys® (the deadline for submitting Trust Submission Forms for these claims is to be annouced).

You can obtain more detailed information regarding these types of claims in the materials available to you on this website.

The Endo GUC Trust will make distributions directly to holders of Notes Claims and Other General Unsecured Claims.  The Endo GUC Trust will make distributions to Distribution Sub-Trusts established for the benefit of Mesh Claims, Ranitidine Claims, Generics Price Fixing Claims and Reverse Payment Claims.  The Distribution Sub-Trusts will make distributions to allowed holders of these claims.

On this website, you will be able to—

• Obtain more information about the Endo GUC Trust, the Distribution Sub-Trusts and the distributions to which you are or may be entitled (see “Frequently Asked Questions”);
• Review and download important documents that govern the Endo GUC Trust, the Distribution Sub-Trusts and the distributions to which you are or may be entitled (see “Important Documents”);
• Review and download the text of notices that you may have received and forms that you may be required to submit, which provide additional information concerning the claims and eligibility for receiving distributions, including, if you hold Notes Claims, the requirement that you tender your Notes Claims no later than September 5, 2024 (see “Notices and Forms”);
• Complete and submit Trust Submission Forms, which are required to be submitted by all holders of claims other than certain institutional holders of Notes Claims (see" File a Trust Submission Form").  The deadline for submission of a Trust Submission Form is September 5, 2024, other than for holders of Generics Price Fixing Claims and Reverse Payment Claims, whose deadline will be announced at a future time;
• Find contact information if you have questions or require assistance regarding the Trust Submission Forms (see “Contact Us”).